Christian Rohlff
Chief Executive Officer Oxford BioTherapeutics Ltd
Christian brings more than 30 years of international experience in oncology drug discovery, platform driven target identification, and strategic partnering. Christian founded and built OBT into a leading oncology company specialising in proteomics driven target discovery for antibody based therapeutics. He established OGAP® Verify, the world’s largest oncology focused proteomics platform, enabling the systematic discovery and validation of novel cancer targets. He has led OBT’s evolution from a discovery start up into a clinical stage oncology supported by multiple strategic collaborations with leading pharmaceutical companies, including Bristol Myers Squibb, Roche, GSK, Boehringer Ingelheim, and ImmunoGen, spanning ADCs, T cell engagers, and multi-specific antibody platforms.
Seminars
- Highlighting differentiated target identification for first-in-class multispecific drugs
- Benchmarking to known approved TCE drugs
- Leveraging dual targeting to expand therapeutic window and patient prevalence
